Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311984 | 0.97 | NAMPT (0.49) | NAMPTALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL4319443 | 0.90 | ALDH1A1 (0.49) | ALDH1A1MAPTSMN1; SMN2HTTCYP2C9 | |
| SCHEMBL4321006 | 0.87 | RBP4 (0.52) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL4317024 | 0.86 | LMNA (0.58) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4429394 | 0.85 | ALDH1A1 (0.55) | NAMPTALDH1A1MAPTSMN1; SMN2HPGD | |
| SCHEMBL4317416 | 0.85 | HTT (0.48) | ALDH1A1MAPTSMN1; SMN2HTTCYP2C9 | |
| SCHEMBL4328352 | 0.85 | HSD11B1 (0.58) | ALDH1A1 | |
| SCHEMBL4320602 | 0.84 | LMNA (0.58) | MAPTSMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4321348 | 0.84 | LMNA (0.55) | ALDH1A1SMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL4314255 | 0.83 | ALDH1A1 (0.48) | ALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | NAMPT 3332/4885ALDH1A1 3104/4885MAPT 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.